The average one-year price target for Alumis (NasdaqGS:ALMS) has been revised to $36.28 / share. This is an increase of 79.14 ...

Alumis Inc. (NASDAQ:ALMS) is among the 14 best booming stocks to buy right now. On January 9, HC Wainwright & Co. lifted its ...

Alumis Inc. is drawing attention with a major share sale and bullish analyst forecasts. The firm aims to fund its immune ...

Alumis (ALMS) stock is soaring after the company announced positive trial results for its plaque psoriasis drug ...

The first purchase involved 117,647 shares, while the second purchase consisted of 294,117 shares.

Alumis (ALMS) has drawn fresh attention after reporting positive topline Phase 3 ONWARD results for envudeucitinib in moderate to severe plaque psoriasis. All primary and secondary endpoints were met, ...

Alumis shares jump 95% after envudeucitinib meets all endpoints in two phase III plaque psoriasis studies, showing strong ...

Alumis shares climb after its psoriasis drug met all late-stage trial goals, showing strong skin clearance, fast results, and ...

Alumis Inc. (NASDAQ:ALMS) is one of the 11 Best New Penny Stocks to Buy Right Now. On May 21, Alumis Inc. (NASDAQ:ALMS) reported that it has completed its merger with ACELYRIN, Inc. As part of this ...

Alumis (ALMS) stock surged after two Phase 3 trial for its lead drug, envudeucitinib, succeeded against plaque psoriasis.

As of January 29, 2025, the average one-year price target for Alumis is $30.60/share. The forecasts range from a low of $25.25 to a high of $39.90. The average price target represents an increase of ...

Alan Colowick, a director at $ALMS, bought 16,104 shares of the company on 04-01-2025 for an estimated $112,309. This trade was reported by Quiver Quantitative using ...